US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.92 ▲+0.49% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.50 ▼-3.18% MSFT $529.30 ▲+0.78%
FinancialContent

Articles published by Halberd Corporation

< Previous 1 2 Next >
News headline image
Halberd Corp. Launches "Halberd Cancer Therapeutics, LTD" Wholly Owned Subsidiary
From Halberd Corporation
Via AccessWire
Topics Intellectual Property
Tickers HALB
News headline image
Halberd's Antibody Effective Against all 4 SARS-CoV-2 Mutations, Including Omicron
From Halberd Corporation
Via AccessWire
Topics Intellectual Property
Tickers HALB
News headline image
Halberd Corporation Update, CEO Letter and 2022 Expectations
From Halberd Corporation
Via AccessWire
Tickers HALB
News headline image
Halberd Creates Subsidiary to Apply Its Patented Technology to Treat Cancer
From Halberd Corporation
Via AccessWire
Tickers HALB
News headline image
Halberd Corp. & Mississippi State University Discuss Animal Testing as Prelude to FDA Certification
From Halberd Corporation
Via AccessWire
Topics Animal Testing
Tickers HALB
News headline image
Halberd Successfully Eliminates Excess Levels of Inflammatory Cytokines
From Halberd Corporation
Via AccessWire
Topics Animal Testing
Tickers HALB
News headline image
Halberd Engages Professional Firm to Proceed with FDA Filings
From Halberd Corporation
Via AccessWire
Tickers HALB
News headline image
Halberd Submits Audited Financials; Files Form-10 as First Step to Up-list to OTCQB
From Halberd Corporation
Via AccessWire
Topics Animal Testing Regulatory Compliance
Tickers HALB
News headline image
Dr. Gregg Sturrus' TEDx Talk(R) Features Halberd's Extracorporeal Treatment of Neurodegenerative Diseases
From Halberd Corporation
Via AccessWire
Tickers HALB
News headline image
Halberd CEO Letter
From Halberd Corporation
Via AccessWire
Tickers HALB
News headline image
Halberd Eliminates E. Coli in 20 Minutes vs. 7-10 Days with Conventional Antibiotics
From Halberd Corporation
Via AccessWire
Topics Animal Testing
Tickers HALB
News headline image
Halberd Entering the Medical Metaverse(TM)
From Halberd Corporation
Via AccessWire
Topics Intellectual Property
Tickers HALB
News headline image
Halberd Continues In-Vitro Successes With Elimination of Protein Linked to Depression
From Halberd Corporation
Via AccessWire
Tickers HALB
News headline image
Infectious Disease Specialist Will Guide Halberd's Extracorporeal Elimination of Disease Antigens in Animals and Then Humans
From Halberd Corporation
Via AccessWire
Tickers HALB
News headline image
Halberd Expands Its Technical Expertise with the Addition of Microbiology Professor
From Halberd Corporation
Via AccessWire
Tickers HALB
News headline image
Halberd's COVID-19 Antibody is the Only One In Competitive Tests to Bind to Omicron Variant
From Halberd Corporation
Via AccessWire
Tickers HALB
News headline image
Halberd Medical Breakthrough for the Treatment of Neurodegenerative Diseases Affecting 36 Million Americans Annually
From Halberd Corporation
Via AccessWire
Tickers HALB
News headline image
Halberd Eliminates 100% of Tau Protein From CSF - The 9th of 10 Target Neurodegenerative Disease Antigens
From Halberd Corporation
Via AccessWire
Tickers HALB
News headline image
Halberd Achieves Landmark Selective Elimination of Tau From an Antigen Mixture
From Halberd Corporation
Via AccessWire
Tickers HALB
News headline image
Halberd CEO Letter: 2021 Year-End & 2022 Outlook
From Halberd Corporation
Via AccessWire
Tickers HALB
News headline image
Halberd, Inc. (HALB) Reports Elimination of Target Antigens, Progressing to Treatments for Neurodegenerative Diseases
From Halberd Corporation
Via AccessWire
Tickers HALB
News headline image
Halberd Corporation Now an Official US Government Contractor
From Halberd Corporation
Via AccessWire
Tickers HALB
News headline image
Halberd Moves Closer to Proving Its Patented Technologies Eliminate Contributors to Neurodegenerative Diseases
From Halberd Corporation
Via AccessWire
Tickers HALB
News headline image
Halberd Eradicates Another Inflammatory Cytokine, Interleukin-12, In Its Continuing Effort To Eliminate Neurodegenerative Diseases
From Halberd Corporation
Via AccessWire
Tickers HALB
News headline image
Halberd Successfully Eradicates Interleukin-1 in Its Continued Progress Toward Eliminating Neurodegenerative Diseases
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers HALB
News headline image
Halberd Follow-up Verification Tests Prove 100% Eradication of TNF-alpha, a Major Contributing Factor to Alzheimer's Disease and PTSD/CTE
From Halberd Corporation
Via AccessWire
Topics Intellectual Property
Tickers HALB
News headline image
Halberd Successfully Eradicates TNF-a, a Major Contributing Factor to Alzheimer’s Disease
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers HALB
News headline image
Halberd Files Additional Extracorporeal Patent Application: Treatment of Covid-19 By Exposure to Tuned Radio Frequency Waves
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers HALB
News headline image
Halberd Successfully Eradicates IL-6, a Critical Factor in PTSD, CTE & Alzheimer’s Disease
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers HALB
News headline image
Halberd Files Provisional Patent on Breakthrough Obesity Treatment
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers HALB
< Previous 1 2 Next >